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Fig 1. Cutaneous intestinal metaplasia. Hematoxylin and
eosin (top). CK20 immunohistochemistry (bottom).
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e18 Lettersconsidered the possibility of an adverse effect to
etanercept. During follow-up, clinical indicators and
MRI findings showed amelioration upon cessation of
treatment. At present, the patient remains under
treatment with ustekinumab at regular doses and
maintains good clinical response without develop-
ment of severe adverse effects.
Given the uncertainty in this area, it seems
reasonable to avoid the use of anti-TNF- agents
and offer an alternative regimen in patients with a
personal or family history of demyelinating disease.
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To the Editor: More than 70% of people with surgi-
cally induced intestinal stomas experience peristo-
mal skin complications, including contact reactions,
malignant neoplasms, preexisting skin diseases,infections, pyoderma gangrenosum, and other ul-
cerations.1 However, to our knowledge, there has
been only 1 reported case in the literature describing
a peristomal skin ulcer with scattered intestinal
tubular glands consistent with cutaneous intestinal
metaplasia,2 which is distinct from lesions of over-
granulation with intestinal metaplasia.1-3 We
describe the second case of cutaneous peristomal
intestinal metaplasia.
A 76-year-old Caucasian female with history of
ulcerative colitis, who had undergone a colectomy at
age 17 resulting in a right lower abdominal ileos-
tomy, presented to the dermatology department with
a 2-year history of persistent stinging and irritation at
the ileostomy site. She denied any changes in her
stoma care. Her ulcerative colitis had been well
controlled since the surgery.
On physical exam there was a red, superficially
erosive plaque extending along the cutaneous
border of the stoma, initially suggestive of irritant
dermatitis. Topical triamcinolone 0.1% ointment
every other day for 1 month was recommended at
that time, without improvement of the erosion or
symptoms on follow-up. Zinc oxide ointment mixed
with triamcinolone ointment was recommended for
an additional 3 months, but lack of significant
improvement on follow-up prompted a punch
biopsy of the plaque.
Histologic examination showed alternating
epidermis with granular layer and colonic-type
glandular mucosa, numerous goblet cells, and no
discernible Paneth cells (Fig 1). The glandular
elements expressed epithelial mucin, and by immu-
nohistochemistry showed strong, diffuse expression
Fig 2. Ileostomy with cutaneous intestinal metaplasia. Before treatment (punch biopsy site at
4 o’clock; left). After treatment (right).
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was not increased. Overall, these findings suggested
a metaplastic phenomenon.
Our patient returned to clinic for suture removal
(Fig 2, left) and at that time was treated with
electrocoagulation on a focal 1-cm region of the
erosion. On follow-up visit, the treated erosion had
evidence of reepithelialization and additional areas
of the erosion were treated, with a total of 4 sessions
of electrocoagulation scheduled 4 weeks apart
(Fig 2, right). Repeat punch biopsy performed at
the conclusion of therapy was consistent with
cicatrix, without evidence of intestinal metaplasia.
Peristomal intestinal metaplasia has been rarely
described.1-4 We report a second case of intestinal
metaplasia in a flat peristomal ulcer without over-
granulation, with an emphasis on management of
this condition. The pathogenesis is hypothesized to
be related to dissemination of intestinal mucosal cells
into the peristomal skin during surgery, or the
promotion of colonic mucosa migration and growth
by bile salts in intestinal contents.5
In 1 previous case report of peristomal intestinal
metaplasia, the authors induced effective reepitheli-
alization of the erosion after 11 electrocoagulation
treatments,2 based on the hypothesis that destruction
of intestinal tubular glands eliminates the secreted
factors that may promote the erosion. Given reports
of primary adenocarcinoma at sites of intestinal
metaplasia,4 when evaluating a patient with a
peristomal erosion recalcitrant to therapy, it is
recommended that a biopsy be performed to
establish the nature of the peristomal skin changes
and to guide proper treatment and management.
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Angiosarcoma of the scalp successfully treated
with pazopanib
To the Editor: Angiosarcoma of the scalp has one of
the worst prognoses among malignant skin tumors.1
Standard treatment guidelines for angiosarcoma do
not currently exist.1 To the best of our knowledge,
this is the first case of angiosarcoma of the scalp
